18 Gennem 48 ugers behandling var andelen af patienter i APTIVUS/ ritonavir- gruppen i forhold til komparator- proteasehæmmer/ ritonavir- gruppen med HIV- 1 RNA < 400 viruspartikler/ ml henholdsvis 30% og 14%, og med HIV- 1 RNA < 50 viruspartikler/ ml henholdsvis 23% og 10%.
Through 48 weeks of treatment, the proportion of patients in the APTIVUS/ ritonavir arm compared to the comparator PI/ ritonavir arm with HIV-1 RNA < 400 copies/ ml was 30% and 14% respectively, and with HIV-1 RNA < 50 copies/ ml was 23% and 10% respectively.